

May 14, 2024

Version 1

Lysosomal GCase (glucocerebrosidase) activity assay V.1

 The Journal of Clinical Investigation

DOI

dx.doi.org/10.17504/protocols.io.8epv5r9jdg1b/v1

Sara Gomes¹, Esther Sammler^{1,2}

¹Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, UK;

²Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, UK

Esther Sammler



Sara Gomes

MRC-PPU

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.8epv5r9jdg1b/v1>

Protocol Citation: Sara Gomes, Esther Sammler 2024. Lysosomal GCase (glucocerebrosidase) activity assay. **protocols.io**
<https://dx.doi.org/10.17504/protocols.io.8epv5r9jdg1b/v1>



License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: May 03, 2024

Last Modified: May 14, 2024

Protocol Integer ID: 99205

Keywords: enzyme activity of lysosomal glucocerebrosidase, lysosomal glucocerebrosidase, glucocerebrosidase, purified lysosome, gba1 inhibitor cbe, enzyme activity, glucopyranoside, hydrolysis of the fluorescent substrate, gba1 activity, whole cell extract, gcase, assay

Funders Acknowledgements:

UK Medical Research Council

Grant ID: MC_UU_00018/1

CSO Scottish Senior Clinical Academic Fellowship

Grant ID: SCAF/18/01

Abstract

Here we report a method to measure enzyme activity of lysosomal glucocerebrosidase (GBA1, GCase) by monitoring the hydrolysis of the fluorescent substrate 4-methylumbelliferyl- β -D-glucopyranoside. The assay is performed at low pH, at which non-lysosomal glucocerebrosidase activity is expected to be low. This is consistent with the abolishment of 4-MUG hydrolysis in the presence of the GBA1 inhibitor CBE. Our data shows that GBA1 activity is significantly increased in purified lysosomes compared to the whole cell extract.

Materials

REAGENTS

- Citric acid (Sigma cat. # 251275)
- Sodium phosphate dibasic (Sigma cat. #567547)
- Sodium taurocholate (Sigma cat. #86339)
- Ethylenediaminetetraacetic acid (EDTA; Sigma cat. #E6511)
- Glycine (Sigma cat. #50046)
- Bovine serum albumin (BSA; Sigma cat. # A7906)
- 4-methylumbelliferyl- β -D-glucopyranoside (4-MUG; Sigma cat. #M3633)
- 4-methylumbelliferone (4-MU; Sigma cat. #M1381)
- Conduritol B epoxide (CBE; Sigma cat. #C5424)
- Dimethyl sulfoxide (DMSO; Sigma cat. #D8418)

BUFFERS

- 0.1M citric acid
- 0.2M sodium phosphate
- Citrate-phosphate buffer, pH 5.4
- 0.5M EDTA, pH 8
- Assay buffer: Citrate-phosphate buffer with 0.25% (w/v) sodium taurocholate, 1mM EDTA, 1% (w/v) BSA
- Stop buffer: 1M Glycine, pH 12.5

EQUIPMENT

- PHERAstar® FS plate reader (Ex/Em = 350/460 FI optical module)
























CONSUMMABLES

- FLUOTAC flat bottom black 96-well plate (Greiner cat. #655076)
- Standard 1mL and 200 μ L Pipette tips (Greiner cat. #686271 and #685261 respectively).




Troubleshooting



Buffer preparation

- 1 **0.1M citric acid:** dissolve  19.2 g citric acid in  1 L dH₂O
- 2 **0.2M sodium phosphate:** dissolve  28.4 g sodium phosphate dibasic in  1 L dH₂O .
- 3 **Citrate-phosphate buffer, pH 5.4:** mix  44.2 mL 0.1M citric acid with  56.8 mL 0.2M sodium phosphate to make 100mL citrate-phosphate buffer,  5.4 .
- 4 **0.5M EDTA:** dissolve  20.8 g EDTA in  80 mL dH₂O Adjust to  8 and top up to  100 mL .
- 5 **Assay buffer:** to make 500 mL assay buffer, add  1.25 g sodium taurocholate ,  5 g BSA , and  1 mL 0.5M EDTA to  500 mL citrate-phosphate buffer .
- 6 **Stop buffer:** dissolve  37.5 g Glycine in  400 mL dH₂O . Adjust to  12.5 and top-up volume to  500 mL .
- 7 **10mM 4-MU calibrator stock solution:** dissolve  17.6 mg 4-MU in  10 mL Stop buffer . Aliquot and store at -20 °C, protected from light.
- 8 **25 mM CBE:** dissolve  5 mg CBE in  1.23 mL DMSO . Aliquot and store at -20°C.

Substrate preparation



- 9 Dissolve  4.2 mg 4-MUG in  2.5 mL assay buffer (final concentration =  5 millimolar (mM)). A sonicator water bath may be used to facilitate dissolution.



Note





Ensure the solution is protected from light. Prepare fresh 4-MUG solution before each assay.

Sample preparation

- 10 Add  5 μg of protein from whole cell extracts or  1 μg of protein from Lyso-IP samples into the wells of a flat bottom black 96-well plate in duplicate.


Note

If CBE treatment is desired, make sure to allocate 2 extra wells per sample for the treatment.

- 11 Top up volume to  80 μL with assay buffer.
- 12 Add  1.2 μL of DMSO or 25mM CBE to each sample well.
- 13 Prepare blank samples in duplicate: add  80 μL to two empty wells.
- 14 Prepare calibrator wells: designate 24 empty wells for the calibrators and add  100 μL assay buffer to each of these wells.

Enzymatic reaction

1h

- 15 Add  20 μL of the 5mM 4-MUG solution prepared in **step 9** to each of the sample and blank wells.

16 Cover the plate and incubate at  37 °C for  01:00:00 .

1h


Note


Ensure the plate is protected from light throughout the incubation.

Preparation of calibrator serial dilutions


17 During the incubation, thaw an aliquot of 10mM 4-MU.

18 Label 11 1.5mL microcentrifuge tubes with numbers 1-11.

19 Add  1 mL stop buffer to tube 1.

20 Add  500 µL stop buffer to tubes 2-11.

21 Add  2 µL 10 mM 4-MU to tube 1.

22 Mix by pipetting up-and-down and transfer  500 µL from tube 1 to tube 2.

23 Repeat **step 22** sequentially for the remaining tubes. At the end, only tube 11 should contain 1 mL.




	A	B	C	D
	Tube	Volume of Stop buffer (µL)	Volume and source of 4-MU (µL)	Final 4-MU concentration (nM)
	1	1000	2 of 10mM stock	20 000



	A	B	C	D
	2	500	500 of tube 1	10 000
	3	500	500 of tube 2	5 000
	4	500	500 of tube 3	2 500
	5	500	500 of tube 4	1 250
	6	500	500 of tube 5	625
	7	500	500 of tube 6	312.5
	8	500	500 of tube 7	156.25
	9	500	500 of tube 8	78.12
	10	500	500 of tube 9	39.06
	11	500	500 of tube 10	19.53

Calibrator concentrations.

Stop reaction and fluorescence measurement


- 24 Add  100 μ L stop buffer to each sample and blank well.
- 25 Add  100 μ L stop buffer to 2 of the calibrator wells. These will be the blanks for the calibration curve.
- 26 Add  100 μ L of each calibrator solution prepared in step 23 to 2 of the calibrator wells.
- 27 Measure fluorescence intensity in a plate reader (Ex/Em = 350/460).

Note

If immediate measurement of fluorescence intensity is not feasible, the plate can be stored at 4 °C , protected from light, for a up to 2 hours.

Data analysis

- 28 Plot the fluorescence intensity of the calibrator against the corresponding amounts of 4-MU in picomoles (pmol). Determine the linear equation representing this relationship.
- 29 Using the calibration curve equation, estimate the amount of released 4-MU in picomoles for the samples.
- 30 Divide the estimated amount of released 4-MU by the amount of protein lysate in milligrams (mg) and the incubation time in minutes. This yields the GCase activity, expressed in terms of released 4-MU in picomoles per milligram per minute (pmol/mg/min).



Hydrolysis of 4-MUG by GCCase.



Protocol references

M. Kedariti *et al.*, 'LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease', *npj Parkinsons Dis.*, vol. 8, no. 1, Art. no. 1, Jul. 2022, doi: [10.1038/s41531-022-00354-3](https://doi.org/10.1038/s41531-022-00354-3).

L. F. Burbulla, S. Jeon, J. Zheng, P. Song, R. B. Silverman, and D. Krainc, 'A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease', *Sci. Transl. Med.*, vol. 11, no. 514, p. eaau6870, Oct. 2019, doi: [10.1126/scitranslmed.aau6870](https://doi.org/10.1126/scitranslmed.aau6870).

J. R. Mazzulli *et al.*, 'Activation of α -Glucocerebrosidase Reduces Pathological α -Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons', *Journal of Neuroscience*, vol. 36, no. 29, pp. 7693–7706, Jul. 2016, doi: [10.1523/JNEUROSCI.0628-16.2016](https://doi.org/10.1523/JNEUROSCI.0628-16.2016).